Better Health for All

Aprea Therapeutics' core business is the development of cancer therapeutics, with its entire business devoted to health improvement.

Its lead product candidates, ATRN-119 and APR-1051, are in clinical development for various tumor types, and early data for ATRN-119 shows tumor shrinkage of 7%, 14%, and 21% in some patients. The company's R&D expenses were $2.5 million in Q1 2025, and as a biopharmaceutical company focused solely on drug development, 100% of its R&D is dedicated to health improvement. However, Aprea holds an extensive patent portfolio for its ATR and WEE1 inhibitors, with four granted U.S. patents, 19 granted non-U.S. patents, and numerous pending applications, potentially extending exclusivity until 2044. There is no mention of patent flexibility or access programs, indicating an inflexible approach to patent enforcement.

Fair Money & Economic Opportunity

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics.

The provided articles confirm its operations are in biopharmaceuticals, with no evidence suggesting it offers lending, deposit, or other financial services to consumers. Therefore, all Key Performance Indicators under 'Fair Money & Economic Opportunity' are not applicable to the company's core business, aligning with the '0' tier definition for non-financial entities.

Honest & Fair Business

No specific, concrete data points were found in the provided article to assess Aprea Therapeutics, Inc. against any of the 'Honest & Fair Business' KPIs.

The article explicitly states that data retrieval was throttled, preventing access to necessary information.

Kind to Animals

No specific information regarding Aprea Therapeutics, Inc.'s animal welfare practices, policies, or performance metrics was found in the provided articles. The articles discuss general industry trends in reducing animal testing and FDA's initiatives to phase out animal testing requirements.

, but do not contain any data specific to the company's operations, product certifications, or R&D investments in animal-free alternatives.

No War, No Weapons

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapeutics. The provided annual report explicitly states that the company is not a defense contractor and is not involved in arms or defense-related activities.

Its R&D focuses on synthetic lethality-based cancer therapeutics. For all KPIs related to arms, defense, dual-use technology, sales to embargoed regimes, peacebuilding investment, conflict divestment, board oversight of defense, export certifications, lobbying on arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance, ethical red lines for weapons, exposure to controversial weapons, war risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, conflict zone procurement, and ethical red lines compliance, the report states "Not applicable." As per the rules, "Not applicable" is not considered a specific, concrete data point for scoring, and therefore, all KPIs are omitted.

Planet-Friendly Business

No specific, concrete data points or facts regarding Aprea Therapeutics, Inc.'s environmental performance, policies, or initiatives were found in the provided articles.

Therefore, no KPIs under the 'Planet-Friendly Business' value can be scored.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points or evidence related to Aprea Therapeutics, Inc.'s performance on any of the KPIs for the 'Respect for Cultures & Communities' ethical value. discusses general industry initiatives for diversity in oncology clinical trials but does not link these practices or outcomes to Aprea Therapeutics.

focuses solely on the company's clinical trial progress and related timelines.

Safe & Smart Tech

No specific, concrete data points were found in the provided articles to assess Aprea Therapeutics, Inc. against the 'Safe & Smart Tech' ethical value. The articles are primarily a financial report and a general cybersecurity statement, neither of which provide the detailed metrics required by the rubric for data protection, cybersecurity, or AI ethics.

For instance, while the company states it is not aware of any material cybersecurity incidents, this does not equate to 'no documented data breaches' as required by the rubric. Similarly, mentions of outsourced IT consultants performing 'proactive patching and monitoring' lack the specific metrics needed to score vulnerability management. All KPIs related to AI ethics, privacy certifications, security training, encryption, data minimization, and user data control also lack explicit evidence.

Zero Waste & Sustainable Products

The provided articles focus exclusively on Aprea Therapeutics' clinical trials for drug candidates and its approach to cancer treatment development. No information or quantitative data related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found.

Therefore, no KPIs under the 'Zero Waste & Sustainable Products' value can be scored based on the given evidence.